NCT00396409View on ClinicalTrials.gov

Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Allergic Asthma
Interventions
DRUG

Depigoid

Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)

DRUG

Omalizumab

anti-IgE (Omalizumab) given during the 2006 core study

DRUG

Placebo

Placebo given during the 2006 core study

Trial Locations (1)

Unknown

Novartis Investigator site, Nuremberg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY